Bicara Therapeutics Inc. published a scientific document on molecular profiling and gene expression analysis in tumor models resistant to KRAS-G12C inhibitor therapy. The document presents data from in vivo and spatial transcriptomics studies, including analysis of gene expression changes in tumors treated with ficerafusp alfa and cetuximab, as well as paired biopsies from patients with HPV-negative recurrent/metastatic head and neck squamous cell carcinoma treated with ficerafusp alfa and pembrolizumab. The full document can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief on November 05, 2025, and is solely responsible for the information contained therein.